Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds
This article was originally published in Scrip
Teva's investigational drug SD-809 (deutetrabenazine) has hit its endpoint in moderate to severe tardive dyskinesia patients in a pivotal Phase II/III trial, top-line results show. The drug, which Teva acquired when it bought Auspex Pharmaceuticals earlier this year, is one of the leading candidates in this neurological disease, for which there are currently no approved treatments in the US.
You may also be interested in...
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.
The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.